RET-positive NSCLC: Translating insights into targeted approaches

touchFOCUS for touchONCOLOGY

In this concise interview, Dr Christine Bestvina discusses the key clinical questions surrounding currently approved RET inhibitors in NSCLC.

The expert:

• Dr Christine Bestvina - University of Chicago, Chicago, IL, USA
  

This touchPODCAST is for HCPs outside the UK. 

This activity is funded by an independent medical education grant from Rigel Pharmaceuticals Inc.

This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchoncology.com